Featured Stories
The shift from high-volume drugs to niche biologics requires a more than just expanded footprints, it demands smarter bioprocess controls, lower COGs early on in development, and cross-functional teams.
Through this certified status, the CDMO will be able to offer its customers targeted, multiplex protein biomarker analysis alongside its human-relevant disease models.
Once limited by poor bioavailability and enzymatic degradation, oral peptides are now on the cusp of becoming the next blockbuster class, reveal Hong Li and Lixia Zhang from BioDuro.
Although the trial did not meet its primary endpoint, EyePoint reported a 42% reduction in overall treatment burden, with most patients requiring zero or one supplemental injection through Week 56.
R&D
Through this certified status, the CDMO will be able to offer its customers targeted, multiplex protein biomarker analysis alongside its human-relevant disease models.
Although the trial did not meet its primary endpoint, EyePoint reported a 42% reduction in overall treatment burden, with most patients requiring zero or one supplemental injection through Week 56.
The money from the oversubscribed Series C round will fund pivotal development of EPI‑321, a clinical-stage epigenetic therapy for FSHD, and supports late-stage development and expansion of manufacturing and pipeline programs.
The new partnership model combines Enzene’s continuous manufacturing platform with facility design, technology transfer, and operational support to help regions build cost-efficient biologics production capacity.
Expansion
By combining Nottingham’s development capabilities with its expanded Haverhill site, Codis creates an integrated UK pathway spanning early-stage development to commercial-scale supply.
The biotech, which was formerly known as EG 427, will use the funds raised in its Series C financing round to advance its lead precision genetic medicine candidate, EG110A.
The appointment of three new senior business development directors across Europe and the U.S, will not only strengthen Codis’ commercial team but will also reinforce its commercial capabilities.
This latest investment by the company combines quality system integration, new high‑speed bottling and expanded cold and ambient storage to support growing U.S. packaging demand.
Dealmaking
After closing an all-stock merger with complement specialist Kira Pharmaceuticals, Jasper Therapeutics is set to create a diversified immunology company.
The companies have entered into a research collaboration to optimize secretion of therapeutic proteins targeting improved durability and efficiency of adeno-associated virus (AAV)-delivered gene medicines.
ten23 health and dsm-firmenich have commenced a scientific collaboration to evaluate pharmaceutical-grade ingredients as potential excipients, seeking new materials to address the challenges of formulation stability and manufacturability for parenteral biologic drugs.
The integration of Autolomous’ autoloMATE system and Cellular Origins’ Constellation platforms aims to standardize and digitize cell therapy manufacturing within existing bioprocess infrastructure.
Strategy
As the divide between upstream output and downstream capability in bioprocessing expands, it is becoming necessary for the biopharma industry to address plant capacity, process intensification, digital connectivity, and business feasibility.
Experts from Alcami break down the latest innovations in lipid-based permeation matrices, continuous direct compression, and advanced analytical workflows designed to bring oral peptides to market safely and predictably.
From highly water-soluble APIs to the strict constraints of personalized therapies, masking unpleasant drug tastes remains a complex engineering challenge, requiring forward-thinking downstream strategies.
With an unprecedented patent cliff looming and complex modalities on the rise, executive teams must decouple capital investment risk from clinical uncertainty by embracing flexible, intensified manufacturing platforms.
Future Biopharma
Once limited by poor bioavailability and enzymatic degradation, oral peptides are now on the cusp of becoming the next blockbuster class, reveal Hong Li and Lixia Zhang from BioDuro.
The shift from high-volume drugs to niche biologics requires a more than just expanded footprints, it demands smarter bioprocess controls, lower COGs early on in development, and cross-functional teams.
Driven by the rise of primary-care biologics and value-based healthcare, oral peptides and proteins are challenging traditional injectable paradigms, reveals Giuseppe De Franza from Adare Pharma Solutions.
According to Britton Jimenez, from Codexis, the future of RNA therapeutics lies beyond traditional synthesis and requires a shift in manufacturing strategy toward advanced and agile platforms and sourcing.
Regulatory
A combination therapy from Gilead and Merck has met its clinical efficacy endpoint, demonstrating non-inferiority to existing daily treatments with no new safety concerns identified in treatment-experienced patient population.
AstraZeneca’s camizestrant has faced a regulatory setback in the U.S., with the FDA extending its review, seeking clearer evidence that early intervention improves long-term outcomes for patients with advanced breast cancer.
The European Commission has approved dupilumab (Dupixent) as the first targeted therapy for chronic spontaneous urticaria (CSU) in children in the EU, broadening its use in type‑2‑driven inflammatory diseases.
The company has revealed that its humanized, glycoengineered Type II anti-CD20 mAb has achieved superior complete remission rates versus tacrolimus in the MAJESTY study.
Upcoming Events
Returning for 2026, the 4th ADC Toxicity Summit is the only dedicated industry forum exclusively focused on preventing, predicting, and mitigating ADC toxicities across preclinical and clinical development.
CPHI Korea is a dynamic meeting place where pharmaceutical suppliers, purchasers and decision makers get together for three days of uninterrupted business.
This year's Spotlight on Artificial Intelligence explores how AI is becoming a co-pilot, enhancing precision, speed, and safety in patient care. Discover AI in action, from diagnosis to delivery, through hands-on sessions, live demonstrations, and immersive learning.
Entering its 6th year, Advanced Therapies Europe 2026 remains an intentionally intimate gathering for senior decision-makers, designed to deliver real impact with each and every conversation.
The 8th RAS-Targeted Drug Development Summit is the industry's only forum dedicated exclusively to translating RAS therapies from early discovery through clinical development.
This year, NLSDays will shine a light on the latest trends shaping the global life science industry while continuing to elevate Nordic success stories.
The 6th iPSC Drug Development Summit is the only meeting exclusively focused on advancing iPSC-based cell therapies, end-to-end.
The Molecular Analysis for Precision Oncology Congress 2026 will take place from 10 to 11 September in London, UK, bringing together leading experts in oncology, molecular diagnostics, and precision medicine for two days of high-level exchange, collaboration, and innovation.
